title: [Isolation of antibodies to Chlamydia and Mycoplasma pneumoniae during the immunosuppressive therapy of patients with inflammatory bowel disease].
abstract: Detection of IgM and IgG Chlamydia and Mycoplasma pneumoniae indicates an aggravation of intracellular infections, including, possibly, due to immunosuppressive therapy. It is possible that the intracellular infection may mediate the occurrence of certain extraintestinal manifestations of inflammatory bowel disease (IBD), such as bronchitis, pneumonia, etc. Chronic persistent chlamydial and mycoplasmal infections lead to disruption of both cellular and humoral immunity, resulting in the formation of autoimmune processes in patients with IBD, and in the future--reduce the immune status against the immunosuppressive therapy. Detection of antibodies to Chlamydia and Mycoplasma pneumoniae accompanies with increased total immunoglobulin IgM, IgG in blood serum. Determining the level of proinflammatory and antiinflammatory cytokines in the acute stage of the disease allows to evaluate the activity of the inflammatory process and the nature of the immune response to intracellular infection.
  
  
  CONCLUSIONS
  to prevent extraintestinal septic complications in patients with IgM antibodies to Chlamydia and Mycoplasma pneumoniae, is recommended to combine the long-term immunosuppressive therapy of IBD with antibiotic therapy, usually with macrolides.
authors: V E
authors: VE
authors: Sagynbaeva
authors: L B
authors: LB
authors: Lazebnik
authors: O V
authors: OV
authors: Kniazev
authors: A I
authors: AI
authors: Parfenov
authors: L I
authors: LI
authors: Efremov
mesh_terms: D000293:Adolescent; D000328:Adult; D010131:Aminosalicylic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000907:Antibodies, Bacterial / Q000097:blood*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D001379:Azathioprine / Q000008:administration & dosage / Q000627:therapeutic use; D016993:Chlamydophila pneumoniae / Q000302:isolation & purification*; D002908:Chronic Disease; D003131:Combined Modality Therapy; D016207:Cytokines / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D056724:Immunity, Humoral / Q000187:drug effects; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000276:immunology / Q000382:microbiology / Q000628:therapy*; D000069285:Infliximab; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation; D008875:Middle Aged; D009177:Mycoplasma pneumoniae / Q000302:isolation & purification*; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D016207:Cytokines; D005938:Glucocorticoids; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007166:Immunosuppressive Agents; D010131:Aminosalicylic Acid; D000069285:Infliximab; D001379:Azathioprine